Cuzzocrea Salvatore, Mazzon Emanuela, Esposito Emanuela, Muià Carmelo, Abdelrahman Maha, Di Paola Rosanna, Crisafulli Concetta, Bramanti Placido, Thiemermann Christoph
Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Messina, Italy.
IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy.
Intensive Care Med. 2007 May;33(5):880-893. doi: 10.1007/s00134-007-0595-1. Epub 2007 Mar 24.
This study investigated the effects of TDZD-8, a potent and selective GSK-3beta inhibitor, on tissue injury caused by ischaemia/reperfusion (I/R) of the gut.
Animal study in the Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Italy.
Splanchnic artery occlusion (SAO) shocked rats.
I/R injury of the intestine was caused by clamping both the superior mesenteric artery and the coeliac trunk for 45 min followed by release of the clamp allowing reperfusion for 1 or 6 h. This procedure results in SAO shock.
Only 10% of the SAO animals survived the entire 6 h reperfusion period. In a separate set of experiments after 60 min of reperfusion animals were killed for histological examination and biochemical studies. Administration of TDZD-8 (1 mg/kg i.v.) 5 min prior to the reperfusion significantly reduced the (a) fall in mean arterial blood pressure, (b) mortality rate, (c) infiltration of the reperfused intestine with polymorphonuclear neutrophils (MPO activity), (d) production of pro-inflammatory cytokines (TNF-alpha and IL-1 beta and (e) histological evidence of gut injury. Administration of TDZD-8 also markedly reduced the immunoreactivity of nitrotyrosine formation and the expression of ICAM-1 and P-selectin during reperfusion.
Based on these findings we propose that TDZD-8 would be useful in the treatment of various ischaemia and reperfusion diseases.
本研究调查了强效选择性糖原合成酶激酶-3β(GSK-3β)抑制剂TDZD-8对肠道缺血/再灌注(I/R)所致组织损伤的影响。
在意大利墨西拿大学医学院临床与实验医学及药理学系进行的动物研究。
内脏动脉闭塞(SAO)休克大鼠。
通过夹闭肠系膜上动脉和腹腔干45分钟,随后松开夹子使肠道再灌注1或6小时,造成肠道I/R损伤。此操作会导致SAO休克。
仅10%的SAO动物在整个6小时再灌注期内存活。在另一组实验中,再灌注60分钟后处死动物进行组织学检查和生化研究。在再灌注前5分钟静脉注射TDZD-8(1毫克/千克)可显著降低:(a)平均动脉血压下降;(b)死亡率;(c)再灌注肠道中多形核中性粒细胞浸润(髓过氧化物酶活性);(d)促炎细胞因子(肿瘤坏死因子-α和白细胞介素-1β)的产生;以及(e)肠道损伤的组织学证据。给予TDZD-8还可显著降低再灌注期间硝基酪氨酸形成的免疫反应性以及细胞间黏附分子-1(ICAM-1)和P-选择素的表达。
基于这些发现,我们认为TDZD-8可用于治疗各种缺血和再灌注疾病。